Literature DB >> 25322196

Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom.

Junko Takeshita1, Shuwei Wang2, Daniel B Shin1, Nehal N Mehta3, Stephen E Kimmel4, David J Margolis1, Andrea B Troxel5, Joel M Gelfand1.   

Abstract

IMPORTANCE: Hypertension is prevalent among patients with psoriasis. The effect of psoriasis and its severity on hypertension control is unknown.
OBJECTIVE: To determine the association between uncontrolled blood pressure and psoriasis, both overall and according to objectively measured psoriasis severity, among patients with diagnosed hypertension. DESIGN, SETTING, AND PARTICIPANTS: Population-based cross-sectional study nested in a prospective cohort drawn from The Health Improvement Network (THIN), an electronic medical records database broadly representative of the general population in the United Kingdom. The study population included a random sample of patients with psoriasis (n = 1322) between the ages of 25 and 64 years in THIN who were included in the Incident Health Outcomes and Psoriasis Events prospective cohort and their age- and practice-matched controls without psoriasis (n = 11,977). All included patients had a diagnosis of hypertension; their psoriasis diagnosis was confirmed and disease severity was classified by their general practitioners. MAIN OUTCOMES AND MEASURES: Uncontrolled hypertension was defined as a systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher based on the blood pressure recorded closest in time to the assessment of psoriasis severity.
RESULTS: There was a significant positive dose-response relationship between uncontrolled hypertension and psoriasis severity as objectively determined by the affected body surface area in both unadjusted and adjusted analyses that controlled for age, sex, body mass index, smoking and alcohol use status, presence of comorbid conditions, and current use of antihypertensive medications and nonsteroidal anti-inflammatory drugs (adjusted odds ratio [aOR], 0.97; 95% CI, 0.82-1.14 for mild psoriasis; aOR, 1.20; 95% CI, 0.99-1.45 for moderate psoriasis; and aOR, 1.48; 95% CI, 1.08-2.04 for severe psoriasis; P = .01 for trend). The likelihood of uncontrolled hypertension among psoriasis overall was also increased, although not statistically significantly so (aOR, 1.10; 95% CI, 0.98-1.24). CONCLUSIONS AND RELEVANCE: Among patients with hypertension, psoriasis was associated with a greater likelihood of uncontrolled hypertension in a dose-dependent manner, with the greatest likelihood observed among those with moderate to severe psoriasis defined by 3% or more of the body surface area affected. Our data suggest a need for more effective blood pressure management, particularly among patients with more severe psoriasis.

Entities:  

Mesh:

Year:  2015        PMID: 25322196      PMCID: PMC4728300          DOI: 10.1001/jamadermatol.2014.2094

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  44 in total

1.  Evaluating hypertension control in a managed care setting.

Authors:  M Alexander; I Tekawa; E Hunkeler; B Fireman; R Rowell; J V Selby; B M Massie; W Cooper
Journal:  Arch Intern Med       Date:  1999 Dec 13-27

2.  The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study.

Authors:  Lars Lund; Jacob Jacobsen; Mette Nørgaard; Joseph K McLaughlin; William J Blot; Michael Borre; Henrik T Sørensen
Journal:  J Urol       Date:  2009-05-17       Impact factor: 7.450

3.  Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.

Authors:  William B White; Christine R West; Jeffrey S Borer; Philip B Gorelick; Lisa Lavange; Sharon X Pan; Ethan Weiner; Kenneth M Verburg
Journal:  Am J Cardiol       Date:  2006-11-10       Impact factor: 2.778

4.  High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients.

Authors:  P Ena; P Madeddu; N Glorioso; D Cerimele; A Rappelli
Journal:  Acta Cardiol       Date:  1985       Impact factor: 1.718

5.  Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses.

Authors:  Abrar A Qureshi; Hyon K Choi; Arathi R Setty; Gary C Curhan
Journal:  Arch Dermatol       Date:  2009-04

6.  The risk of stroke in patients with psoriasis.

Authors:  Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel
Journal:  J Invest Dermatol       Date:  2009-05-21       Impact factor: 8.551

Review 7.  The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents.

Authors:  Edward P Armstrong; Daniel C Malone
Journal:  Clin Ther       Date:  2003-01       Impact factor: 3.393

8.  Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy.

Authors:  Srinivas Sriramula; Masudul Haque; Dewan S A Majid; Joseph Francis
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis.

Authors:  Mayte Suárez-Fariñas; Katherine Li; Judilyn Fuentes-Duculan; Karen Hayden; Carrie Brodmerkel; James G Krueger
Journal:  J Invest Dermatol       Date:  2012-07-05       Impact factor: 8.551

10.  The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies.

Authors:  A W Armstrong; C T Harskamp; E J Armstrong
Journal:  Nutr Diabetes       Date:  2012-12-03       Impact factor: 5.097

View more
  29 in total

1.  Response to 'Kidney disease in moderate-to-severe psoriasis: a critical appraisal'.

Authors:  J Wan; J M Gelfand
Journal:  Br J Dermatol       Date:  2016-02       Impact factor: 9.302

2.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.

Authors:  George Martin; Bruce E Strober; Craig L Leonardi; Joel M Gelfand; Andrew Blauvelt; Arthur Kavanaugh; Linda Stein Gold; Brian Berman; Ted Rosen; Eggert Stockfleth
Journal:  J Clin Aesthet Dermatol       Date:  2016-09-01

Review 3.  National Heart, Lung, and Blood Institute Working Group Report on Salt in Human Health and Sickness: Building on the Current Scientific Evidence.

Authors:  Young S Oh; Lawrence J Appel; Zorina S Galis; David A Hafler; Jiang He; Amanda L Hernandez; Bina Joe; S Ananth Karumanchi; Christine Maric-Bilkan; David Mattson; Nehal N Mehta; Gwendolyn Randolph; Michael Ryan; Kathryn Sandberg; Jens Titze; Eser Tolunay; Glenn M Toney; David G Harrison
Journal:  Hypertension       Date:  2016-06-20       Impact factor: 10.190

4.  Psoriasis and the risk of diabetes: A prospective population-based cohort study.

Authors:  Marilyn T Wan; Daniel B Shin; Rebecca A Hubbard; Megan H Noe; Nehal N Mehta; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-11-08       Impact factor: 11.527

5.  Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis.

Authors:  Li-Hao Huang; Bernd H Zinselmeyer; Chih-Hao Chang; Brian T Saunders; Andrew Elvington; Osamu Baba; Thomas J Broekelmann; Lina Qi; Joseph S Rueve; Melody A Swartz; Brian S Kim; Robert P Mecham; Helge Wiig; Michael J Thomas; Mary G Sorci-Thomas; Gwendalyn J Randolph
Journal:  Cell Metab       Date:  2018-11-08       Impact factor: 27.287

6.  Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study.

Authors:  Kashif Jafri; Christie M Bartels; Daniel Shin; Joel M Gelfand; Alexis Ogdie
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-11-28       Impact factor: 4.794

Review 7.  Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms.

Authors:  Kaitlyn M Yim; April W Armstrong
Journal:  Rheumatol Int       Date:  2016-05-24       Impact factor: 2.631

Review 8.  Psoriasis and comorbid diseases: Implications for management.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527

Review 9.  Psoriasis and comorbid diseases: Epidemiology.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527

Review 10.  Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.

Authors:  Michael S Garshick; Nicole L Ward; James G Krueger; Jeffrey S Berger
Journal:  J Am Coll Cardiol       Date:  2021-04-06       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.